People: Novartis AG (NOVN.VX)

NOVN.VX on Virt-X Level 1

98.05CHF
9:43am EDT
Change (% chg)

CHF1.05 (+1.08%)
Prev Close
CHF97.00
Open
CHF96.90
Day's High
CHF98.10
Day's Low
CHF96.90
Volume
3,068,257
Avg. Vol
5,218,308
52-wk High
CHF102.70
52-wk Low
CHF76.05

Search Stocks

van Arkel, Paul 

Mr. Paul van Arkel has been Head of Corporate Strategy and External Affairs at Novartis AG since May 2013. Prior to joining Novartis, Mr. van Arkel was a partner at McKinsey & Company, specializing in pharmaceuticals and medical products. At McKinsey, he led the company’s pharmaceutical marketing work in Europe, the Middle East, and Africa, as well as its work on pharmaceutical launches worldwide. Mr. van Arkel previously served as a consultant and later a partner at Monitor Group, initially focusing on corporate strategy across industries, and eventually moving to marketing and sales in pharmaceuticals and medical devices. Mr. van Arkel received a diploma in public administration from Leiden University in the Netherlands, and a master’s degree in business administration from Erasmus University, also in the Netherlands.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Joerg Reinhardt

1,900,810

Joseph Jimenez

13,226,300

Ulrich Lehner

1,328,210

Harry Kirsch

2,344,290

Peter Kornicker

--

Felix Ehrat

4,321,510
As Of  30 Dec 2013
Search Stocks